NASDAQ:VIVO - Meridian Bioscience Stock Price, Price Target & More

$14.60 -0.15 (-1.02 %)

(As of 04/20/2018 10:30 AM ET)

Previous Close$14.75

Today's Range$14.60 - $14.85

52-Week Range$13.23 - $16.45

Volume31,385 shs

Average Volume293,037 shs

Market Capitalization$626.16 million

P/E Ratio21.76

Dividend Yield3.38%

Beta0.96

About Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; H. pylori to detect stomach ulcers; respiratory products; and women's health and sexually transmitted diseases Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances

Sub-IndustryHealth Care Supplies

SectorMedical

SymbolNASDAQ:VIVO

CUSIP58958410

Webwww.meridianbioscience.com

Phone513-271-3700

Debt

Debt-to-Equity Ratio0.28%

Current Ratio5.82%

Quick Ratio3.96%

Price-To-Earnings

Trailing P/E Ratio21.76

Forward P/E Ratio20.28

P/E GrowthN/A

Sales & Book Value

Annual Sales$200.77 million

Price / Sales3.08

Cash Flow$1.0377 per share

Price / Cash14.07

Book Value$4.02 per share

Price / Book3.63

Profitability

EPS (Most Recent Fiscal Year)$0.67

Net Income$21.55 million

Net Margins10.46%

Return on Equity17.00%

Return on Assets11.59%

Miscellaneous

Employees640

Outstanding Shares42,310,000

How to Become a New Pot Stock Millionaire

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience declared a quarterly dividend on Wednesday, January 24th. Investors of record on Monday, February 5th will be paid a dividend of $0.125 per share on Thursday, February 15th. This represents a $0.50 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend is Friday, February 2nd. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its earnings results on Thursday, January, 25th. The company reported $0.15 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.14 by $0.01. The company had revenue of $52.30 million for the quarter, compared to the consensus estimate of $49 million. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. The company's revenue was up 11.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.15 earnings per share. View Meridian Bioscience's Earnings History.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Meridian Bioscience.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided EPS guidance of $0.65-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.68. The company issued revenue guidance of $207-212 million, compared to the consensus revenue estimate of $207.18 million.

What price target have analysts set for VIVO?

1 brokers have issued 1 year target prices for Meridian Bioscience's shares. Their predictions range from $16.00 to $16.00. On average, they expect Meridian Bioscience's share price to reach $16.00 in the next twelve months. View Analyst Ratings for Meridian Bioscience.

Who are some of Meridian Bioscience's key competitors?

Some companies that are related to Meridian Bioscience include Intellia Therapeutics (NTLA), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Quotient (QTNT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Achieve Life Sciences (ACHV) and BG Medicine (BGMD).

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:

Mr. John A. Kraeutler, Exec. Chairman (Age 70)
Ms. Melissa A. Lueke, Exec. VP, CFO, Principal Accounting Officer & Sec. (Age 55)
Ms. Susan D. Rolih, Exec. VP of Global Regulatory & Quality Systems (Age 69)
Mr. John P. Kenny, CEO & Director (Age 49)
Mr. Lawrence J. Baldini, Exec. VP & Pres of Global Operations (Age 59)

Has Meridian Bioscience been receiving favorable news coverage?

News coverage about VIVO stock has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Meridian Bioscience earned a news sentiment score of 0.04 on Accern's scale. They also gave media stories about the company an impact score of 45.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $14.60.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $626.16 million and generates $200.77 million in revenue each year. The company earns $21.55 million in net income (profit) each year or $0.67 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.

MarketBeat Community Rating for Meridian Bioscience (VIVO)

Community Ranking:		1.7 out of 5 ()
Outperform Votes:		135 (Vote Outperform)
Underperform Votes:		272 (Vote Underperform)
Total Votes:		407

MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Meridian Bioscience (NASDAQ:VIVO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Meridian Bioscience in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 9.59%. The high price target for VIVO is $16.00 and the low price target for VIVO is $16.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.00	2.00	1.75	1.75
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$16.00	$16.00	$11.50	$14.00
Price Target Upside:	9.59% upside	0.00% downside	23.08% downside	6.35% downside

Meridian Bioscience (NASDAQ:VIVO) Consensus Price Target History

Price Target History for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/26/2018	Canaccord Genuity	Boost Price Target	Hold -> Hold	$14.00 -> $16.00	Low
3/28/2017	CL King	Initiated Coverage	Neutral -> Neutral		High
1/31/2017	Craig Hallum	Downgrade	Buy -> Hold		N/A
1/25/2017	Piper Jaffray	Set Price Target	Sell	$9.00	N/A
7/29/2016	Hilliard Lyons	Downgrade	Buy -> Hold		N/A

(Data available from 4/20/2016 forward)

Meridian Bioscience (NASDAQ:VIVO) Earnings History and Estimates Chart

Earnings by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Earnings Estimates

2018 EPS Consensus Estimate: $0.72

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.17	$0.17	$0.17
Q2 2018	1	$0.22	$0.22	$0.22
Q3 2018	1	$0.17	$0.17	$0.17
Q4 2018	1	$0.16	$0.16	$0.16

Meridian Bioscience (NASDAQ VIVO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/26/2018		$0.20					N/A
1/25/2018	Q1 2018	$0.14	$0.15	$49.00 million	$52.30 million	View	N/A
11/9/2017	Q4 2017	$0.15	$0.15	$48.28 million	$49.70 million	View	N/A
7/27/2017	Q3 2017	$0.16	$0.16	$49.13 million	$50.14 million	View	N/A
4/28/2017	Q2 2017	$0.19	$0.22	$51.16 million	$54.13 million	View	N/A
1/25/2017	Q1 2017	$0.20	$0.15	$51.15 million	$46.80 million	View	N/A
11/10/2016	Q4 2016	$0.14	$0.14	$47.17 million	$47.00 million	View	N/A
7/28/2016	Q3	$0.22	$0.21	$52.85 million	$50.70 million	View	N/A
4/28/2016	Q2	$0.2420	$0.24	$52.10 million	$51.30 million	View	N/A
1/27/2016	Q1	$0.21	$0.21	$48.60 million	$47.20 million	View	N/A
11/5/2015	Q4	$0.21	$0.20	$45.70 million	$47.10 million	View	N/A
7/23/2015	Q3	$0.22	$0.22	$48.60 million	$48.20 million	View	N/A
4/23/2015	Q115	$0.24	$0.24	$50.50 million	$51.55 million	View	N/A
1/22/2015	Q414	$0.19	$0.19	$46.20 million	$48.00 million	View	N/A
11/6/2014	Q4	$0.22	$0.20	$48.94 million	$46.70 million	View	N/A
7/24/2014	Q3	$0.22	$0.21	$47.96 million	$47.20 million	View	N/A
4/24/2014	Q214	$0.27	$0.24	$52.18 million	$50.13 million	View	N/A
1/22/2014	Q114	$0.18	$0.18	$47.59 million	$44.80 million	View	N/A
11/7/2013	Q313	$0.23	$0.22	$49.24 million	$48.96 million	View	N/A
7/25/2013	Q3 2013	$0.21	$0.24	$47.00 million	$47.10 million	View	N/A
4/25/2013	Q2 2013	$0.24	$0.24	$49.66 million	$47.26 million	View	N/A
1/23/2013	Q1 2013	$0.19	$0.20	$44.34 million	$45.40 million	View	N/A
11/8/2012	Q412	$0.19	$0.21	$43.22 million	$43.70 million	View	N/A
7/26/2012		$0.22	$0.21			View	N/A
4/26/2012		$0.21	$0.23			View	N/A
1/25/2012		$0.19	$0.17			View	N/A
11/10/2011		$0.19	$0.18			View	N/A
7/21/2011		$0.21	$0.17			View	N/A
4/21/2011		$0.20	$0.20			View	N/A
1/20/2011		$0.19	$0.15			View	N/A
11/11/2010	Q4 2010	$0.18	$0.15			View	N/A
7/20/2010	Q3 2010	$0.18	$0.17			View	N/A
4/20/2010	Q2 2010	$0.14	$0.15			View	N/A
1/21/2010	Q1 2010	$0.23	$0.22			View	N/A
11/12/2009	Q4 2009	$0.21	$0.22			View	N/A
7/16/2009	Q3 2009	$0.20	$0.21			View	N/A
4/16/2009	Q2 2009	$0.22	$0.18			View	N/A
1/22/2009	Q1 2009	$0.20	$0.20			View	N/A
11/12/2008	Q4 2008	$0.18	$0.19			View	N/A
7/17/2008	Q3 2008	$0.19	$0.19			View	N/A
4/17/2008	Q2 2008	$0.19	$0.18			View	N/A
1/22/2008	Q1 2008	$0.17	$0.18			View	N/A

(Earnings results data provided by Zacks Investment Research)

Meridian Bioscience (NASDAQ:VIVO) Dividend Information

Meridian Bioscience pays an annual dividend of $0.50 per share, with a dividend yield of 3.42%. VIVO's most recent quarterly dividend payment was Thursday, February 15. Meridian Bioscience pays out 74.63% of its earnings out as a dividend.

Most Recent Dividend:	2/15/2018
Annual Dividend:	$0.50
Dividend Yield:	3.42%
Payout Ratio:	74.63% (Trailing 12 Months of Earnings) 69.44% (Based on This Year's Estimates) 64.94% (Based on Next Year's Estimates)

Dividend Payments by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/24/2018	Quarterly	$0.1250	3.52%	2/2/2018	2/5/2018	2/15/2018
11/8/2017	Quarterly	$0.1250	3.44%	11/17/2017	11/20/2017	11/30/2017
7/27/2017	Quarterly	$0.1250	3.55%	8/3/2017	8/7/2017	8/17/2017
4/27/2017	quarterly	$0.1250	3.33%	5/4/2017	5/8/2017	5/18/2017
1/25/2017	quarterly	$0.1250	3.91%	2/2/2017	2/6/2017	2/16/2017
11/10/2016	Quarterly	$0.20	4.6%	11/17/2016	11/21/2016	12/1/2016
7/28/2016	quarterly	$0.20	4.13%	8/4/2016	8/8/2016	8/18/2016
4/28/2016	quarterly	$0.20	4.19%	5/5/2016	5/9/2016	5/19/2016
1/27/2016	quarterly	$0.20	4.29%	2/4/2016	2/8/2016	2/18/2016
11/5/2015	quarterly	$0.20	3.89%	11/12/2015	11/16/2015	11/27/2015
7/23/2015	quarterly	$0.20	4.28%	7/30/2015	8/3/2015	8/13/2015
4/23/2015	quarterly	$0.20	4.18%	4/30/2015	5/4/2015	5/14/2015
1/22/2015	quarterly	$0.20	4.51%	1/29/2015	2/2/2015	2/13/2015
11/6/2014	quarterly	$0.20	4.75%	11/13/2014	11/17/2014	11/28/2014
7/24/2014	quarterly	$0.20	3.99%	7/31/2014	8/4/2014	8/14/2014
4/24/2014	quarterly	$0.20	4.05%	5/1/2014	5/5/2014	5/15/2014
1/22/2014	quarterly	$0.20	3.13%	1/30/2014	2/3/2014	2/14/2014
11/7/2013	quarterly	$0.19	3.04%	11/14/2013	11/18/2013	11/29/2013
7/25/2013	quarterly	$0.19	3.13%	8/1/2013	8/5/2013	8/15/2013
4/25/2013	quarterly	$0.19	3.88%	5/1/2013	5/4/2013	5/14/2013
12/4/2012	quarterly	$0.19			12/14/2012	12/24/2012

(Data available from 1/1/2013 forward)

Meridian Bioscience (NASDAQ VIVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 90.95%

Insider Trading History for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ VIVO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/23/2018	John Mcilwraith	Director	Buy	1,000	$14.03	$14,030.00	4,000
2/7/2018	John Mccune Jr. Rice	Director	Buy	1,000	$14.75	$14,750.00
8/24/2017	John A Kraeutler	Chairman	Buy	7,000	$13.67	$95,690.00	345,230
2/2/2017	Melissa Lueke	CFO	Buy	4,000	$12.59	$50,360.00	167,071
1/26/2017	Lawrence Baldini	EVP	Buy	4,000	$12.70	$50,800.00	106,934
12/2/2016	Vecheslav A Elagin	EVP	Sell	7,883	$17.30	$136,375.90	52,926
11/30/2016	Dwight E Ellingwood	Director	Buy	1,020	$17.12	$17,462.40	7,000
11/16/2016	Richard Eberly	EVP	Sell	4,926	$17.00	$83,742.00	48,719
11/4/2016	John A Kraeutler	Chairman	Buy	5,000	$16.13	$80,650.00	316,683
11/3/2016	Lawrence Baldini	EVP	Buy	4,900	$16.00	$78,400.00	95,501
8/11/2016	John Mcilwraith	Director	Buy	1,000	$19.57	$19,570.00	3,000
4/29/2016	Catherine Sazdanoff	Director	Buy	7,700	$19.20	$147,840.00	7,700
12/9/2015	Vecheslav A Elagin	EVP	Sell	7,500	$19.75	$148,125.00	54,459
12/1/2015	Richard Eberly	EVP	Sell	4,934	$19.61	$96,755.74	46,219
3/2/2015	Marviette D Johnson	VP	Sell	1,917	$19.91	$38,167.47
1/23/2015	Dwight E Ellingwood	Director	Buy	1,980	$17.74	$35,125.20
12/1/2014	Susan Rolih	EVP	Sell	11,219	$16.46	$184,664.74
11/21/2014	Dwight E Ellingwood	Director	Buy	1,000	$16.08	$16,080.00
11/18/2014	John A Kraeutler	CEO	Sell	10,500	$16.20	$170,100.00
11/18/2014	Melissa Lueke	CFO	Sell	6,713	$16.20	$108,750.60
11/11/2014	David Phillips	Director	Buy	10,000	$16.89	$168,900.00
6/13/2014	Robert J Ready	Director	Sell	2,700	$20.03	$54,081.00
12/5/2013	Vecheslav Elagin	EVP	Sell	4,141	$23.74	$98,307.34	50,500
11/22/2013	Susan Rolih	EVP	Sell	9,086	$24.18	$219,699.48	106,702
11/21/2013	Richard Eberly	EVP	Sell	4,926	$24.50	$120,687.00	40,755
11/19/2013	Lawrence Baldini	VP	Sell	4,926	$24.26	$119,504.76	75,500
11/11/2013	John Kraeutler	CEO	Sell	5,250	$25.27	$132,667.50	270,718
7/26/2013	Lawrence Baldini	VP	Sell	32,000	$24.14	$772,480.00
5/1/2013	John A Kraeutler	CEO	Buy	5,000	$19.63	$98,150.00
12/3/2012	Lawrence Baldini	VP	Sell	32,500	$20.00	$650,000.00
11/13/2012	Robert J Ready	Director	Sell	1,800	$19.46	$35,028.00

(Data available from 1/1/2013 forward)

Meridian Bioscience (NASDAQ VIVO) News Headlines

Source:

Date	Headline
	Meridian Bioscience (VIVO) to Release Quarterly Earnings on Thursday www.americanbankingnews.com - April 19 at 3:16 AM
	Meridian Bioscience (VIVO) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 13 at 1:35 PM
	Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Quarterly Sales of $54.00 Million www.americanbankingnews.com - April 6 at 5:16 AM
	Meridian Bioscience (VIVO) Cut to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 5 at 9:00 PM
	Brokerages Expect Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.20 Per Share www.americanbankingnews.com - April 4 at 1:22 AM
	Zacks Investment Research Downgrades Meridian Bioscience (VIVO) to Hold www.americanbankingnews.com - March 29 at 3:00 PM
	Meridian Bioscience (VIVO) Realigns Organizational Structure www.streetinsider.com - March 21 at 5:53 PM
	Meridian Bioscience (VIVO) Raised to Buy at Zacks Investment Research www.americanbankingnews.com - March 21 at 2:13 PM
	Meridian Bioscience Realigns Business Structure - Quick Facts www.rttnews.com - March 21 at 8:16 AM
	Meridian Bioscience Realigns Organizational Structure finance.yahoo.com - March 21 at 8:16 AM
	Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 Million www.americanbankingnews.com - March 19 at 2:26 AM
	Meridian Bioscience, Inc. (VIVO) Expected to Post Earnings of $0.20 Per Share www.americanbankingnews.com - March 17 at 11:14 PM
	Meridian Bioscience (VIVO) Raised to "Hold" at BidaskClub www.americanbankingnews.com - March 10 at 10:28 PM
	Connors Investor Services Inc. Decreases Stake in Meridian Bioscience, Inc. (VIVO) www.americanbankingnews.com - March 5 at 1:54 PM
	Meridian Bioscience, Inc. (VIVO) Position Lifted by Martingale Asset Management L P www.americanbankingnews.com - March 3 at 11:50 AM
	Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 Million www.americanbankingnews.com - March 2 at 2:28 AM
	Spark Investment Management LLC Has $2.89 Million Stake in Meridian Bioscience, Inc. (VIVO) www.americanbankingnews.com - February 28 at 5:44 PM
	American Century Companies Inc. Purchases Shares of 137,306 Meridian Bioscience, Inc. (VIVO) www.americanbankingnews.com - February 27 at 4:06 AM
	Insider Buying: Meridian Bioscience, Inc. (VIVO) Director Buys 1,000 Shares of Stock www.americanbankingnews.com - February 26 at 12:16 PM
	Contrasting Meridian Bioscience (VIVO) and Lombard Medical (EVARF) www.americanbankingnews.com - February 18 at 7:02 PM
	Meridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $53.35 Million www.americanbankingnews.com - February 14 at 12:46 PM
	Lawsuit for Investors in Meridian Bioscience, Inc. (NASDAQ: VIVO) Shares Announced by Shareholders Foundation finance.yahoo.com - February 12 at 3:33 PM
	Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS www.americanbankingnews.com - February 12 at 5:12 AM
	Meridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 Shares www.americanbankingnews.com - February 8 at 4:20 AM
	Active-Investors: Free Post Earnings Research Report: Meridian's Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4% www.finanznachrichten.de - February 5 at 8:00 AM
	Free Post Earnings Research Report: Meridian’s Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4% finance.yahoo.com - February 5 at 8:00 AM
	Meridian Bioscience (VIVO) Downgraded to Sell at BidaskClub www.americanbankingnews.com - February 3 at 1:38 PM
	William Blair Comments on Meridian Bioscience, Inc.'s FY2019 Earnings (VIVO) www.americanbankingnews.com - January 29 at 7:46 AM
	Meridian Bioscience, Inc. (VIVO) Declares Quarterly Dividend of $0.13 www.americanbankingnews.com - January 28 at 7:31 AM
	Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.26 Million www.americanbankingnews.com - January 28 at 5:48 AM
	Meridian Bioscience (VIVO) Price Target Increased to $16.00 by Analysts at Canaccord Genuity www.americanbankingnews.com - January 26 at 3:18 PM
	Head-To-Head Analysis: Zimmer Biomet (ZBH) & Meridian Bioscience (VIVO) www.americanbankingnews.com - January 26 at 1:30 PM
	Meridian Bioscience, Inc. (VIVO) Expected to Announce Earnings of $0.14 Per Share www.americanbankingnews.com - January 26 at 5:22 AM
	Meridian Bioscience (VIVO) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - January 25 at 9:26 AM
	Meridian Bioscience (VIVO) Releases FY18 Earnings Guidance www.americanbankingnews.com - January 25 at 9:14 AM
	Meridian Bioscience beats 1Q profit forecasts finance.yahoo.com - January 25 at 7:55 AM
	Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance finance.yahoo.com - January 25 at 7:55 AM
	Meridian Bioscience (VIVO) Set to Announce Quarterly Earnings on Thursday www.americanbankingnews.com - January 24 at 10:58 PM
	Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Operating Results on Thursday, January 25, 2018 finance.yahoo.com - January 19 at 4:44 PM
	FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018 finance.yahoo.com - January 16 at 4:22 PM
	The Klein Law Firm Reminds Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018 (VIVO) finance.yahoo.com - January 15 at 4:23 PM
	UPCOMING DEADLINE: The Klein Law Firm Reminds Investors of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018 (VIVO) finance.yahoo.com - January 13 at 10:25 AM
	MERIDIAN BIOSCIENCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Meridian Bioscience, Inc. - VIVO finance.yahoo.com - January 13 at 10:25 AM
	Glancy Prongay & Murray Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Meridian Bioscience, Inc. (VIVO) finance.yahoo.com - January 13 at 10:25 AM
	VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors ... www.businesswire.com - January 11 at 4:28 PM
	Greater Cincinnati firm faces lawsuits linked to FDA warning, stock dip finance.yahoo.com - January 11 at 4:28 PM
	Zacks: Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $49.74 Million www.americanbankingnews.com - January 11 at 1:58 PM
	VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the Firm finance.yahoo.com - January 10 at 4:23 PM
	SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018 finance.yahoo.com - January 10 at 10:39 AM
	Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the Firm (VIVO) www.businesswire.com - January 8 at 4:29 PM

Meridian Bioscience (NASDAQ:VIVO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Meridian Bioscience (NASDAQ:VIVO) Income Statement, Balance Sheet and Cash Flow Statement

Meridian Bioscience (NASDAQ VIVO) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff